Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Obstetrics and Gynecology
|
December 1, 1976
The retained cervical stump. A 25-year experience
J H Pratt, J A Jefferies
Gynecologic Oncology
|
September 28, 2000
Low-grade endometrial stromal sarcoma of the ectocervix after therapy for breast cancer
C H Boardman, M J Webb, J A Jefferies
American Journal of Obstetrics and Gynecology
|
April 1, 1984
Upper genital tract abnormalities and pregnancy outcome in diethylstilbestrol-exposed progeny
R H Kaufman, K Noller, E Adam, et al.
Gynecologic Oncology
|
April 1, 1981
Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil
G D Malkasian, D G Decker, S J Green, et al.
Obstetrics and Gynecology
|
July 1, 1985
Effects of progestational agents in treatment of endometrial carcinoma
K C Podratz, P C O'Brien, G D Malkasian, et al.
Cancer Treatment Reports
|
February 1, 1987
Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma
J H Edmonson, G W McCormack, J E Krook, et al.
Gynecologic Oncology
|
September 1, 1987
Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma
J H Edmonson, J E Krook, J F Hilton, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
January 1, 1978
Chemotherapeutic sensitivity of minimal residual disease following surgical excision of ovarian carcinoma
J H Edmonson, T R Fleming, D G Decker, et al.
Cancer Treatment Reports
|
February 1, 1979
Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease
J H Edmonson, T R Fleming, D G Decker, et al.
Cancer
|
November 15, 1992
Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin
J H Edmonson, L C Hartmann, H J Long, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Obstetrics and Gynecology
|
December 1, 1976
The retained cervical stump. A 25-year experience
J H Pratt, J A Jefferies
Gynecologic Oncology
|
September 28, 2000
Low-grade endometrial stromal sarcoma of the ectocervix after therapy for breast cancer
C H Boardman, M J Webb, J A Jefferies
American Journal of Obstetrics and Gynecology
|
April 1, 1984
Upper genital tract abnormalities and pregnancy outcome in diethylstilbestrol-exposed progeny
R H Kaufman, K Noller, E Adam, et al.
Gynecologic Oncology
|
April 1, 1981
Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil
G D Malkasian, D G Decker, S J Green, et al.
Obstetrics and Gynecology
|
July 1, 1985
Effects of progestational agents in treatment of endometrial carcinoma
K C Podratz, P C O'Brien, G D Malkasian, et al.
Cancer Treatment Reports
|
February 1, 1987
Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma
J H Edmonson, G W McCormack, J E Krook, et al.
Gynecologic Oncology
|
September 1, 1987
Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma
J H Edmonson, J E Krook, J F Hilton, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
January 1, 1978
Chemotherapeutic sensitivity of minimal residual disease following surgical excision of ovarian carcinoma
J H Edmonson, T R Fleming, D G Decker, et al.
Cancer Treatment Reports
|
February 1, 1979
Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease
J H Edmonson, T R Fleming, D G Decker, et al.
Cancer
|
November 15, 1992
Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin
J H Edmonson, L C Hartmann, H J Long, et al.
Page
of 2